Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Curtin

Showing results (1-10 of 480) with videos related to

Pageof 48
Sort By:
Biochemical Society Transactions|January 6, 2023
Targeting the DNA damage response for cancer therapyNicola J Curtin
Transactions of the American Ophthalmological Society|January 1, 1977
The posterior staphyloma of pathologic myopiaB J Curtin
Cancers|March 4, 2020
The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and SerendipityNicola J Curtin
Ophthalmology|May 1, 1979
Physiologic vs pathologic myopia: genetics vs environmentB J Curtin
Cell Cycle (Georgetown, Tex.)|December 9, 2014
PARP inhibitors target ATM+p53-defective gastric cancerNicola J Curtin
Ophthalmic Surgery|January 1, 1976
Cataract extraction in pathological myopiaB J Curtin
Acta Ophthalmologica. Supplement|January 1, 1988
Anterior chamber anomalies and pathologic myopiaB J Curtin
Acta Ophthalmologica. Supplement|January 1, 1988
Adult myopiaB J Curtin
British Journal of Pharmacology|May 21, 2013
Inhibiting the DNA damage response as a therapeutic manoeuvre in cancerN J Curtin
Nature Reviews. Cancer|November 24, 2012
DNA repair dysregulation from cancer driver to therapeutic targetNicola J Curtin
Pageof 48

Showing results (1-10 of 480) with videos related to

Sort By:
Pageof 48
Biochemical Society Transactions|January 6, 2023
Targeting the DNA damage response for cancer therapyNicola J Curtin
Transactions of the American Ophthalmological Society|January 1, 1977
The posterior staphyloma of pathologic myopiaB J Curtin
Cancers|March 4, 2020
The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and SerendipityNicola J Curtin
Ophthalmology|May 1, 1979
Physiologic vs pathologic myopia: genetics vs environmentB J Curtin
Cell Cycle (Georgetown, Tex.)|December 9, 2014
PARP inhibitors target ATM+p53-defective gastric cancerNicola J Curtin
Ophthalmic Surgery|January 1, 1976
Cataract extraction in pathological myopiaB J Curtin
Acta Ophthalmologica. Supplement|January 1, 1988
Anterior chamber anomalies and pathologic myopiaB J Curtin
Acta Ophthalmologica. Supplement|January 1, 1988
Adult myopiaB J Curtin
British Journal of Pharmacology|May 21, 2013
Inhibiting the DNA damage response as a therapeutic manoeuvre in cancerN J Curtin
Nature Reviews. Cancer|November 24, 2012
DNA repair dysregulation from cancer driver to therapeutic targetNicola J Curtin
Pageof 48